Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2019-06-11

Clinical Trial Update: A Study of Galcanezumab in Participants With Chronic Cluster Headache [Phase 3]

View source ↗

Summary

Phase 3 clinical trial update for galcanezumab in chronic cluster headache completed with results posted in 2019.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Galcanezumab (galcanezumab)

Snippet

Sponsor: Eli Lilly and Company | Conditions: Chronic Cluster Headache | Phase 3 | Status: COMPLETED | Results posted: 2019-06-11